Termine
Präsentationen
Aktie
Aktueller Finanzbericht
News
Neueste
Tweets
vor 2 Wochen 3 Tage
@MorphoSys
We announced the #biomarker that was introduced in MAR19 to the B-MIND study with #tafasitamab&bendamustine. We bel… https://t.co/GWqw93IFYF
vor 2 Wochen 3 Tage
@MorphoSys
#MorphoSys second quarter 2019, with strong financial results, further advanced pipeline and great news on… https://t.co/5DVv6ekvAq
vor 2 Wochen 3 Tage
@MorphoSys
#tafasitamab is gaining traction – #MorphoSys yesterday announced an intention to submit amarketing authorization a… https://t.co/Us7V0Fu9oZ
vor 1 Monat 2 Wochen
@MorphoSys
Engineering the medicines of tomorrow.
MorphoSys CSO Dr. Markus Enzelberger on CD47 - SIRP alpha inhibitors - an ex… https://t.co/LihIdSS6xI
vor 2 Monate 12 Stunden
@MorphoSys
MorphoSys is happy to host a Meet the Team Event at the Yale Club in New York. Strong news flow around our key asse… https://t.co/riu1ooXBxp
vor 3 Monate 2 Wochen
@MorphoSys
MOR208 is now tafasitamab!
Tafasitamab - our proprietary Fc-enhanced antibody targeting CD19 in late stage clinica… https://t.co/8xy5KL3fkR
vor 8 Monate 2 Wochen
@MorphoSys
Great News! MorphoSys’ licensee Janssen reported data from the phase 3 head-to-head ECLIPSE study with Tremfya®(gus… https://t.co/z7kHQKPAU3
vor 9 Monate 1 Tag
@MorphoSys
Great news for Japanese patients: Tremfya® now approved for palmoplantar pustulosis in Japan. Congrats to our licen… https://t.co/03l5oPE7IR
vor 9 Monate 1 Woche
@MorphoSys
Phase 2 study with guselkumab started by our licensee Janssen in chronic skin disease hidradenitis suppurativa (HS)… https://t.co/opXoqzNPvH
Medien und Investoren
Dr. Sarah Fakih
Vice President/Head of Corporate Communications & Investor Relations
Telefon +49 89 89927 26663
Dr. Julia Neugebauer
Director Corporate Communications & Investor Relations
Telefon +49 89 89927 179
Dr.Verena Kupas
Manager Corporate Communications & Investor Relations
Telefon +49 89 89927 26814
Alexandra Goller
Director Corporate Communications & Investor Relations
Telefon +49 89 89927 332
Nicola Thomas
Specialist Corporate Communications & Investor Relations - Koordination & Administration
Telefon +49 89 89927 249